Maximus, Inc. $MMS Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC reduced its stake in shares of Maximus, Inc. (NYSE:MMS) by 95.4% in the 1st quarter, Holdings Channel reports. The fund owned 23,701 shares of the health services provider’s stock after selling 493,848 shares during the period. Janus Henderson Group PLC’s holdings in Maximus were worth $1,519,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. Royal Bank of Canada increased its holdings in shares of Maximus by 146.2% during the 1st quarter. Royal Bank of Canada now owns 19,732 shares of the health services provider’s stock valued at $1,345,000 after purchasing an additional 11,716 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Maximus by 0.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,476 shares of the health services provider’s stock worth $2,351,000 after buying an additional 221 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Maximus by 7.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 180,690 shares of the health services provider’s stock worth $12,321,000 after buying an additional 11,754 shares in the last quarter. Jane Street Group LLC grew its position in Maximus by 941.2% during the first quarter. Jane Street Group LLC now owns 98,273 shares of the health services provider’s stock valued at $6,701,000 after buying an additional 88,835 shares during the period. Finally, Sivia Capital Partners LLC purchased a new position in Maximus in the second quarter valued at $204,000. 97.21% of the stock is owned by institutional investors and hedge funds.

Key Maximus News

Here are the key news stories impacting Maximus this week:

• Positive Sentiment: Fiscal Q3 adjusted earnings were $2.22 per share, ahead of analyst estimates of approximately $2.20–$2.21 and up from $2.16 a year earlier. Higher margins also supported the quarter’s bottom-line performance. Maximus Q3 Earnings Beat Estimates, Increase Year Over Year
• Positive Sentiment: The earnings beat, year-over-year EPS growth and stronger margins indicate that Maximus is maintaining profitability even as sales soften. Maximus Q3 Earnings Beat Estimates
• Neutral Sentiment: Management’s fiscal Q3 earnings call focused on the quarterly performance and updated outlook, providing investors with additional context on operating trends and the company’s expectations for the remainder of fiscal 2026. Maximus Q3 2026 Earnings Call Transcript
• Negative Sentiment: Revenue was $1.28 billion, below the $1.33 billion consensus estimate and down 5.1% year over year. The shortfall suggests softer demand or project timing is limiting growth. Maximus Fiscal Q3 Earnings Snapshot
• Negative Sentiment: Maximus reduced fiscal 2026 EPS guidance to $7.90–$8.20, below the consensus estimate of $8.43. Revenue guidance of $5.2–$5.4 billion remains broadly in line with expectations at the midpoint, but the lower profit outlook is a key overhang for MMS. Updated Maximus Fiscal 2026 Guidance

Maximus Price Performance

Maximus stock opened at $59.21 on Monday. The stock has a market capitalization of $3.10 billion, a P/E ratio of 8.75 and a beta of 0.59. The company’s fifty day moving average price is $58.63 and its 200 day moving average price is $67.24. The company has a debt-to-equity ratio of 0.90, a quick ratio of 2.42 and a current ratio of 2.42. Maximus, Inc. has a 1 year low of $52.73 and a 1 year high of $100.00.

Maximus (NYSE:MMS) last posted its quarterly earnings data on Thursday, August 6th. The health services provider reported $2.22 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.01. The company had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.33 billion. Maximus had a net margin of 7.07% and a return on equity of 24.91%. The firm’s revenue for the quarter was down 5.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.16 earnings per share. Maximus has set its FY 2026 guidance at 7.900-8.200 EPS. As a group, equities research analysts anticipate that Maximus, Inc. will post 8.05 earnings per share for the current fiscal year.

Maximus Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Friday, August 14th will be given a dividend of $0.33 per share. This represents a $1.32 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Friday, August 14th. Maximus’s dividend payout ratio is 19.76%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Weiss Ratings lowered shares of Maximus from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 20th. Wall Street Zen lowered Maximus from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Zacks Research cut Maximus from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Two investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company presently has a consensus rating of “Hold”.

About Maximus

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.